RU2362780C2 - Nogo-a-нейтрализующие иммуноглобулины для лечения неврологических заболеваний - Google Patents

Nogo-a-нейтрализующие иммуноглобулины для лечения неврологических заболеваний Download PDF

Info

Publication number
RU2362780C2
RU2362780C2 RU2006123481/13A RU2006123481A RU2362780C2 RU 2362780 C2 RU2362780 C2 RU 2362780C2 RU 2006123481/13 A RU2006123481/13 A RU 2006123481/13A RU 2006123481 A RU2006123481 A RU 2006123481A RU 2362780 C2 RU2362780 C2 RU 2362780C2
Authority
RU
Russia
Prior art keywords
antibody
seq
nogo
analogue
functional fragment
Prior art date
Application number
RU2006123481/13A
Other languages
English (en)
Russian (ru)
Other versions
RU2006123481A (ru
Inventor
Джонатан Хенри ЭЛЛИС (GB)
Джонатан Хенри ЭЛЛИС
Александр ЭОН-ДЮВАЛЬ (GB)
Александр ЭОН-ДЮВАЛЬ
Роберт Айан ГРАНДИ (GB)
Роберт Айан ГРАНДИ
Фархана ХУССЕЙН (GB)
Фархана Хуссейн
Рут МАКАДАМ (GB)
Рут Макадам
Кристофер ПЛАМПТОН (GB)
Кристофер ПЛАМПТОН
Рабиндер Кумар ПРИНДЖХА (GB)
Рабиндер Кумар Принджха
Пол Александер УИЛСОН (GB)
Пол Александер УИЛСОН
Original Assignee
Глаксо Груп Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0329711A external-priority patent/GB0329711D0/en
Priority claimed from GB0329684A external-priority patent/GB0329684D0/en
Application filed by Глаксо Груп Лимитед filed Critical Глаксо Груп Лимитед
Publication of RU2006123481A publication Critical patent/RU2006123481A/ru
Application granted granted Critical
Publication of RU2362780C2 publication Critical patent/RU2362780C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2006123481/13A 2003-12-22 2004-12-20 Nogo-a-нейтрализующие иммуноглобулины для лечения неврологических заболеваний RU2362780C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0329711A GB0329711D0 (en) 2003-12-22 2003-12-22 Antibodies
GB0329684A GB0329684D0 (en) 2003-12-22 2003-12-22 Method
GB0329684.5 2003-12-22
GB0329711.6 2003-12-22

Publications (2)

Publication Number Publication Date
RU2006123481A RU2006123481A (ru) 2008-01-27
RU2362780C2 true RU2362780C2 (ru) 2009-07-27

Family

ID=34712703

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006123481/13A RU2362780C2 (ru) 2003-12-22 2004-12-20 Nogo-a-нейтрализующие иммуноглобулины для лечения неврологических заболеваний

Country Status (28)

Country Link
US (4) US7988964B2 (fr)
EP (3) EP2213684A3 (fr)
JP (2) JP4901480B2 (fr)
KR (1) KR101150548B1 (fr)
AR (1) AR048912A1 (fr)
AT (1) ATE440866T1 (fr)
AU (1) AU2004303585B2 (fr)
BR (1) BRPI0417959A (fr)
CA (1) CA2549956C (fr)
CY (1) CY1110530T1 (fr)
DE (1) DE602004022871D1 (fr)
DK (1) DK1711530T3 (fr)
ES (1) ES2330444T3 (fr)
HK (1) HK1100144A1 (fr)
HR (1) HRP20090527T1 (fr)
IL (1) IL176206A (fr)
IS (1) IS2739B (fr)
MA (1) MA28289A1 (fr)
MX (1) MXPA06007190A (fr)
MY (1) MY144612A (fr)
NO (1) NO20062767L (fr)
NZ (1) NZ548013A (fr)
PL (1) PL1711530T3 (fr)
PT (1) PT1711530E (fr)
RU (1) RU2362780C2 (fr)
SI (1) SI1711530T1 (fr)
TW (1) TWI329649B (fr)
WO (2) WO2005061544A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8680239B2 (en) 2000-12-22 2014-03-25 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Use of RGM and its modulators
US8906864B2 (en) 2005-09-30 2014-12-09 AbbVie Deutschland GmbH & Co. KG Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use
US9102722B2 (en) 2012-01-27 2015-08-11 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration
US9175075B2 (en) 2009-12-08 2015-11-03 AbbVie Deutschland GmbH & Co. KG Methods of treating retinal nerve fiber layer degeneration with monoclonal antibodies against a retinal guidance molecule (RGM) protein
US9605069B2 (en) 2008-02-29 2017-03-28 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM a protein and uses thereof
RU2774446C2 (ru) * 2016-06-08 2022-06-21 Сучжоу Коннект Биофармасьютикалс, Лтд Антитело для специфического связывания с рецептором интерлейкина 4

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0228832D0 (en) * 2002-12-10 2003-01-15 Novartis Ag Organic compound
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
GB0321997D0 (en) * 2003-09-19 2003-10-22 Novartis Ag Organic compound
AU2004303585B2 (en) 2003-12-22 2010-12-23 Glaxo Group Limited NOGO-a neutralising immunoglobulins for treatment of neurological diseases
WO2007003421A2 (fr) * 2005-07-05 2007-01-11 Glaxo Group Limited Immunoglobulines
KR101667623B1 (ko) * 2005-11-30 2016-10-19 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
PL1954718T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Przeciwciała skierowane przeciwko A globulomerowi, ich reszty wiążące antygeny, odpowiednie hybrydomy, kwasy nukleinowe, wektory, komórki gospodarze, sposoby wytwarzania tych przeciwciał, kompozycje zawierające te przeciwciała, zastosowania tych przeciwciał i sposoby stosowania tych przeciwciał
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
US8663635B2 (en) 2006-03-21 2014-03-04 The Regents Of The University Of California N-cadherin: target for cancer diagnosis and therapy
US20090291976A1 (en) * 2006-06-27 2009-11-26 Peter Andrew Ferchmin Neuronal circuit-dependent neuroprotection by interaction between nicotinic receptors
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008070780A1 (fr) * 2006-12-07 2008-06-12 Novartis Ag Anticorps antagonistes contre ephb3
EP2124952A2 (fr) * 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Méthode de traitement d'amyloïdoses
US20110105724A1 (en) * 2007-08-16 2011-05-05 Stephanie Jane Clegg Novel compounds
DK2207808T3 (da) * 2007-11-02 2013-08-05 Novartis Ag Forbedrede Nogo-A-bindingsmolekyler samt deres farmaceutiske anvendelse
EA201001603A1 (ru) * 2008-04-04 2011-06-30 Те Риджентс Оф Те Юниверсити Оф Калифорния Антитела против кадгерина, блокирующие рост опухоли, ангиогенез и метастазирование
JP2011527317A (ja) * 2008-07-11 2011-10-27 グラクソ グループ リミテッド Ｎｏｇｏ−ａアンタゴニストによる筋萎縮性側索硬化症の治療
US10266585B2 (en) 2009-08-28 2019-04-23 The Board Of Regents Of The Univerity Of Texas System Methods of treating brain injury
MX336196B (es) 2010-04-15 2016-01-11 Abbvie Inc Proteinas de union a amiloide beta.
WO2012004773A1 (fr) 2010-07-09 2012-01-12 Universite De Geneve Nouvelles utilisations d'inhibiteurs de nogo-a et procédés associés
MX358739B (es) 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.
CA2817973C (fr) 2010-10-15 2019-06-25 The Board Of Regents Of The University Of Texas System Anticorps qui lient des oligomeres amyloides
EP2632490A4 (fr) 2010-10-29 2014-10-22 Immunogen Inc Nouvelles molécules se liant au récepteur egf et immunoconjugués de celles-ci
CN105399831A (zh) 2010-10-29 2016-03-16 伊缪诺金公司 非拮抗性egfr结合分子及其免疫偶联物
EP2794010A4 (fr) 2011-11-21 2015-10-21 Immunogen Inc Méthode de traitement de tumeurs résistantes aux thérapies egfr par un conjugué anticorps egfr-agent cytotoxique
WO2013106485A2 (fr) * 2012-01-09 2013-07-18 The Scripps Research Institute Régions déterminant la complémentarité ultralongues et utilisations associées
CA2876284A1 (fr) 2012-07-05 2014-01-09 Glaxo Group Limited Regime posologique optimal d'un anticorps anti-nogo-a dans le traitement de la sclerose laterale amyotrophique
CN115340607A (zh) 2015-05-04 2022-11-15 西托姆克斯治疗公司 抗cd166抗体、可活化抗cd166抗体及其使用方法
US20180362660A1 (en) * 2016-05-09 2018-12-20 Schickwann Tsai Anti-penumbra monoclonal antibodies for detection and therapy of normal and abnormal B lymphocytes
EA202090247A1 (ru) * 2017-07-14 2020-05-12 Цитомкс Терапьютикс, Инк. Антитела против cd166 и их применения
WO2020068058A1 (fr) * 2018-09-25 2020-04-02 Academia Sinica Anticorps anti-siglec, composition pharmaceutique le comprenant, et leurs utilisations
CA3158491A1 (fr) 2019-10-24 2021-04-29 Novago Therapeutics Ag Nouveaux anticorps anti-nogo-a
WO2022119932A1 (fr) * 2020-12-02 2022-06-09 Agilent Technologies, Inc. Anticorps anti-cd10 humains destinés à une utilisation dans des protocoles d'immunohistochimie (ihc) pour diagnostiquer un cancer
WO2024041450A1 (fr) * 2022-08-22 2024-02-29 舒泰神（北京）生物制药股份有限公司 Anticorps pour reconnaître de manière spécifique nogo-a et son utilisation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3935074A (en) * 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
DK0804419T3 (da) 1994-05-27 2003-11-24 Glaxosmithkline Spa Quinolinderivater som tachykinin NK 3-receptor-antagonister
CZ304224B6 (cs) * 1998-11-06 2014-01-15 Schwab Monoklonální protilátka
FR2792199B3 (fr) 1999-04-13 2001-05-18 Sanofi Sa Utilisation de l'osanetant pour la preparation de medicaments utiles dans le traitement des troubles de l'humeur
US20030113891A1 (en) * 2000-02-11 2003-06-19 Lawrence Blatt Method and reagent for the inhibition of NOGO and NOGO receptor genes
GB0101313D0 (en) * 2001-01-18 2001-02-28 Glaxo Group Ltd Assay
WO2003088926A2 (fr) * 2002-04-17 2003-10-30 Pharmacia & Upjohn Company Llc Compositions et methodes de traitement de la maladie d'alzheimer
GB0228832D0 (en) * 2002-12-10 2003-01-15 Novartis Ag Organic compound
CA2522649A1 (fr) * 2003-04-16 2004-11-04 Biogen Idec Ma Inc. Traitement d'etats impliquant des plaques amyloides
GB0318727D0 (en) 2003-08-08 2003-09-10 Smithkline Beecham Corp Novel compounds
GB0321997D0 (en) * 2003-09-19 2003-10-22 Novartis Ag Organic compound
AU2004303585B2 (en) * 2003-12-22 2010-12-23 Glaxo Group Limited NOGO-a neutralising immunoglobulins for treatment of neurological diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Wiessner et al., "Anti-Nogo-A antibody infusion 24 hours after experimental stroke improved behavioral outcome and corticospinal plasticity in normotensive and spontaneously hypertensive rats", J. Cereb. Blood Flow Metab., 2003, 23 (2), стр.154-165. *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8680239B2 (en) 2000-12-22 2014-03-25 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Use of RGM and its modulators
US8906864B2 (en) 2005-09-30 2014-12-09 AbbVie Deutschland GmbH & Co. KG Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use
US9605069B2 (en) 2008-02-29 2017-03-28 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM a protein and uses thereof
US9175075B2 (en) 2009-12-08 2015-11-03 AbbVie Deutschland GmbH & Co. KG Methods of treating retinal nerve fiber layer degeneration with monoclonal antibodies against a retinal guidance molecule (RGM) protein
US9102722B2 (en) 2012-01-27 2015-08-11 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration
US9365643B2 (en) 2012-01-27 2016-06-14 AbbVie Deutschland GmbH & Co. KG Antibodies that bind to repulsive guidance molecule A (RGMA)
US10106602B2 (en) 2012-01-27 2018-10-23 AbbVie Deutschland GmbH & Co. KG Isolated monoclonal anti-repulsive guidance molecule A antibodies and uses thereof
RU2774446C2 (ru) * 2016-06-08 2022-06-21 Сучжоу Коннект Биофармасьютикалс, Лтд Антитело для специфического связывания с рецептором интерлейкина 4

Also Published As

Publication number Publication date
EP2213684A3 (fr) 2011-05-18
US20060029603A1 (en) 2006-02-09
EP1711530A2 (fr) 2006-10-18
CA2549956A1 (fr) 2005-07-07
MY144612A (en) 2011-10-14
DE602004022871D1 (de) 2009-10-08
IL176206A (en) 2012-02-29
AU2004303585B2 (en) 2010-12-23
US7988964B2 (en) 2011-08-02
TWI329649B (en) 2010-09-01
MA28289A1 (fr) 2006-11-01
KR20060129290A (ko) 2006-12-15
AU2004303585A1 (en) 2005-07-07
HK1100144A1 (en) 2007-09-07
MXPA06007190A (es) 2006-08-23
NZ548013A (en) 2009-04-30
CY1110530T1 (el) 2015-04-29
IS2739B (is) 2011-06-15
CA2549956C (fr) 2016-04-12
JP2007537145A (ja) 2007-12-20
US20140147435A1 (en) 2014-05-29
US7780964B2 (en) 2010-08-24
AR048912A1 (es) 2006-06-14
HRP20090527T1 (en) 2009-11-30
US20110054149A1 (en) 2011-03-03
IL176206A0 (en) 2006-10-05
PT1711530E (pt) 2009-10-22
BRPI0417959A (pt) 2007-03-27
WO2005061544A3 (fr) 2005-08-18
KR101150548B1 (ko) 2012-07-06
JP4901480B2 (ja) 2012-03-21
SI1711530T1 (sl) 2010-01-29
ES2330444T3 (es) 2009-12-10
EP2213684A2 (fr) 2010-08-04
IS8506A (is) 2006-06-12
DK1711530T3 (da) 2009-12-14
WO2005061545A2 (fr) 2005-07-07
RU2006123481A (ru) 2008-01-27
WO2005061544A2 (fr) 2005-07-07
JP2008504220A (ja) 2008-02-14
EP1706426A2 (fr) 2006-10-04
NO20062767L (no) 2006-09-20
TW200533680A (en) 2005-10-16
US20070065430A1 (en) 2007-03-22
EP1711530B1 (fr) 2009-08-26
WO2005061545A3 (fr) 2005-08-18
ATE440866T1 (de) 2009-09-15
PL1711530T3 (pl) 2010-01-29

Similar Documents

Publication Publication Date Title
RU2362780C2 (ru) Nogo-a-нейтрализующие иммуноглобулины для лечения неврологических заболеваний
RU2421464C2 (ru) Человеческие антитела к il-13 и их терапевтическое применение
RU2376316C2 (ru) Человеческие антитела против человеческого 4-1вв (cd137)
US20180002388A1 (en) FUSION PROTEINS OF NATURAL HUMAN PROTEIN FRAGMENTS TO CREATE ORDERLY MULTIMERIZED IMMUNOGLOBULIN Fc COMPOSITIONS
JP2019527543A5 (fr)
CA2189015A1 (fr) Procedes et compositions s'appliquant au traitement de la glomerulonephrite et d'autres maladies inflammatoires
RU2012156938A (ru) Антитела против gdf8 человека
JP2019527194A5 (fr)
RU2011110169A (ru) Антитела против ccr2
CA2494008A1 (fr) Anticorps de glycoproteine associee a la myeline (mag)
RU2012118636A (ru) Молекула, специфически связывающаяся с rsv
RU2008129080A (ru) Средства и способы лечения опухолевых заболеваний
JP2006512899A5 (fr)
RU2016122340A (ru) Il-17a-связующий агент и способы его применения
EP2033971A1 (fr) Domaines de protéines recombinantes des protéines morphogénétiques osseuses (BMP) de la famille des Repulsive Guidance Molecule (RGM) et leurs fragments fonctionnels ainsi que leur utilisation
US10954292B2 (en) Anti-PACAP antibody
RU2009133789A (ru) Способы лечения глазных болезней
JP2009519025A5 (fr)
RU2009136913A (ru) Биспецифические связывающие агенты с межвидовой специфичностью
JP2015513903A5 (fr)
EA201890805A1 (ru) Биспецифические антитела против cd3*cd19
RU2008138541A (ru) Способы разрушения клеток с использованием эффекторных функций анти-epha4 антител
JP2014527806A5 (ja) 改変抗体およびその作製方法
AR045765A1 (es) Moleculas de union a cd45 y uso terapeutico
RU2014108815A (ru) Новые антитела к фосфорилхолину

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20171221